Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
PEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$198.68 - $310.00
Previous CloseN/A
Volume93.15K
Average Volume (3M)417.99K
Market Cap
$10.16B
Enterprise Value$9.87B
Total Cash (Recent Filing)$421.77M
Total Debt (Recent Filing)$220.53M
Price to Earnings (P/E)67.1
Beta0.46
Next Earnings
Nov 05, 2025EPS Estimate
0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding38,999,130
10 Day Avg. Volume324,766
30 Day Avg. Volume417,994
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.71
Enterprise Value/Gross Profit11.60
Enterprise Value/Ebitda50.95
Forecast
1Y Price Target
$308.93Price Target Upside22.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Market ExpansionIf STORM PE data are positive, there could be a broader industry move toward mechanical thrombectomy, which benefits companies involved in this treatment.
Product AdoptionRuby XL makes a meaningful difference in pelvic congestion and varicoceles procedures, as well as embolizing aneurysms and large arterial or venous occlusions, which represent about 20% of coil procedures.
Revenue GrowthThe upcoming Thunderbolt launch is expected to nearly double PEN's revenue per stroke procedure, driving stronger neuro thrombectomy growth and improving gross margins.
Bears Say
Market CompetitionPenumbra's products represent only 10% of the doctor's usage in PE procedures, with Inari being preferred for certain advantages.
Product LimitationsRuby XL is not a product that allows someone to do procedures they would not do beforehand, and it would not grow the market for procedures or grow the patient population for referral.
Penumbra News
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $198.68 and its highest was $310.00 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is $10.16B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Nov 05, 2025 which is in 21 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Jul 29, 2025. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.825 by $0.035.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 0.93.
How many shares outstanding does Penumbra have?
Penumbra has 38,999,130 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.86 in its last earnings report, beating expectations of $0.825. Following the earnings report the stock price went up 11.913%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in PEN
Penumbra Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$308.93 (22.02% Upside)
$308.93 (22.02% Upside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 72.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.59%
12-Months-Change
Fundamentals
Return on Equity
12.03%
Trailing 12-Months
Asset Growth
9.14%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. is a global healthcare company specializing in innovative medical devices designed for the treatment of various vascular and neurovascular conditions. The company develops a range of products, including catheter-based devices for thrombectomy, embolization, and other minimally invasive procedures. Penumbra operates primarily in the interventional segment of the medical device industry, focusing on creating solutions that enhance patient outcomes and streamline clinical workflows.
PEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with strong revenue growth driven by the U.S. thrombectomy business and strategic investments in new products like RUBY XL. However, challenges remain in the international segment due to China and a slower-growing stroke market.View all PEN earnings summariesPEN Stock 12 Month Forecast
Average Price Target
$308.93
▲(22.02% Upside)
Technical Analysis
Ownership Overview
2.95% Insiders
40.18% Mutual Funds
― Other Institutional Investors
34.86% Public Companies and
Individual Investors